title: Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.
abstract: Hydroxyurea-derived clinical and biological benefits and safety were retrospectively studied for 123 adult patients from 2 sickle cell disease referral centers during a total follow-up of 654 patient-years and total hydroxyurea exposure of 549 patient-years. Fifty-six adverse events occurred (incidence: 12%/patient-year), with leg ulcers being the most frequent. Adverse events could arise at any time and were usually reversible. No malignancy was observed. Clinical and biological benefits of our cohort were similar to those previously reported. Based on this relatively long retrospective study, the risk/benefit ratio for moderate hydroxyurea doses was satisfactory.
authors.affiliation: Sickle Cell Disease Center, Groupe Hospitalier Albert-Chenevier - Henri-Mondor, AP-HP, Créteil, France. ruben.nzouakou@hmn.aphp.fr
authors.forename: Ruben
authors.initials: R
authors.lastname: Nzouakou
authors.forename: Dora
authors.initials: D
authors.lastname: Bachir
authors.forename: Anne
authors.initials: A
authors.lastname: Lavaud
authors.forename: Anoosha
authors.initials: A
authors.lastname: Habibi
authors.forename: Ketty
authors.initials: K
authors.lastname: Lee
authors.forename: François
authors.initials: F
authors.lastname: Lionnet
authors.forename: Anne
authors.initials: A
authors.lastname: Hulin
authors.forename: Hélène
authors.initials: H
authors.lastname: Jouault
authors.forename: Claude
authors.initials: C
authors.lastname: Préhu
authors.forename: Françoise
authors.initials: F
authors.lastname: Roudot-Thoraval
authors.forename: Robert
authors.initials: R
authors.lastname: Girot
authors.forename: Frédéric
authors.initials: F
authors.lastname: Galactéros
mesh_terms: D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications / Q000188:drug therapy*; D000986:Antisickling Agents; D002648:Child; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D007871:Leg Ulcer / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000986:Antisickling Agents; D006918:Hydroxyurea